Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Obese Subjects with OSA
NCT06565871Phase 2Not yet recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 2 trial of HRS9531 in obesity, obstructive sleep apnea (OSA), sponsored by Fujian Shengdi Pharmaceuticals. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
HRS9531
03
Conditions
obesityobstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT06565871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565871.